Business Context and Reporting Period
Ares Capital Corporation (ARCC) filed a Form 8-K on January 31, 2020, reporting the entry into a material definitive agreement. The registrant is a Maryland corporation with principal executive offices in New York, NY.
Key Financial Metrics
This filing does not report revenue, profit, cash flow, margins, or liquidity metrics. The document focuses exclusively on the amendment of a revolving funding facility.
- Facility Type: Revolving funding facility (CP Funding Facility).
- Previous Commitment: $1.275 billion.
- New Commitment: $1.525 billion.
- Previous Maturity Date: January 3, 2024.
- New Maturity Date: January 31, 2025.
- Previous Reinvestment Period End: January 3, 2022.
- New Reinvestment Period End: January 31, 2023.
Material Changes
On January 31, 2020, Ares Capital Corporation and its subsidiary, Ares Capital CP Funding LLC, amended their agreement with Wells Fargo Bank, National Association, Bank of America, N.A., and other lenders. The material changes include:
- Increased total commitments by $250 million.
- Extended the facility maturity by approximately one year.
- Extended the reinvestment period by approximately one year.
- Modified certain loan portfolio concentration limits.
Guidance, Outlook, and Risks
The filing contains no forward-looking guidance, management commentary on future performance, or specific risk factors beyond the standard incorporation of the amendment terms. The filing notes that the description of the amendment is a summary and is qualified by the full text of the agreement filed as Exhibit 10.1.
Investor Verification Checklist
- Verify the full terms of the "CP Amendment" in Exhibit 10.1 to confirm specific details on modified loan portfolio concentration limits.
- Confirm the identity of all lenders and the agent (Wells Fargo Bank, National Association) in the amended facility.
- Review subsequent filings to determine if the increased capacity was drawn upon or if the extended reinvestment period impacts future capital deployment strategies.